Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

A study of parabens and bisphenol A in surface water and fish brain tissue from the Greater Pittsburgh Area.

Renz L, Volz C, Michanowicz D, Ferrar K, Christian C, Lenzner D, El-Hefnawy T.

Ecotoxicology. 2013 May;22(4):632-41. doi: 10.1007/s10646-013-1054-0. Epub 2013 Mar 13.

PMID:
23479059
2.

Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice.

Steinman RA, Yang Q, Gasparetto M, Robinson LJ, Liu X, Lenzner DE, Hou J, Smith C, Wang Q.

Int J Cancer. 2013 Apr 15;132(8):1741-50. doi: 10.1002/ijc.27851. Epub 2012 Oct 17.

3.

17β Hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma.

Szajnik M, Szczepanski MJ, Elishaev E, Visus C, Lenzner D, Zabel M, Glura M, DeLeo AB, Whiteside TL.

Gynecol Oncol. 2012 Dec;127(3):587-94. doi: 10.1016/j.ygyno.2012.08.010. Epub 2012 Aug 17.

4.

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.

Foon KA, Mehta D, Lentzsch S, Kropf P, Marks S, Lenzner D, Pietragallo L, Sulecki M, Tarhini A, Boyiadzis M.

Blood. 2012 Mar 29;119(13):3184-5. doi: 10.1182/blood-2012-01-408047. No abstract available.

PMID:
22461474
5.

Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms.

Austin F, Mavanur A, Sathaiah M, Steel J, Lenzner D, Ramalingam L, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA.

Ann Surg Oncol. 2012 May;19(5):1386-93. doi: 10.1245/s10434-012-2241-6.

6.

Longitudinal evaluation of cancer-associated biomarkers before and after weight loss in RENEW study participants: implications for cancer risk reduction.

Linkov F, Maxwell GL, Felix AS, Lin Y, Lenzner D, Bovbjerg DH, Lokshin A, Hennon M, Jakicic JM, Goodpaster BH, DeLany JP.

Gynecol Oncol. 2012 Apr;125(1):114-9. doi: 10.1016/j.ygyno.2011.12.439. Epub 2011 Dec 22.

7.

Race and health disparities in patient refusal of surgery for early-stage non-small cell lung cancer: a SEER cohort study.

Mehta RS, Lenzner D, Argiris A.

Ann Surg Oncol. 2012 Mar;19(3):722-7. doi: 10.1245/s10434-011-2087-3. Epub 2011 Sep 27.

PMID:
21947698
8.

Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.

Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP, Vlad AM.

Cancer Immunol Immunother. 2011 Jul;60(7):975-84. doi: 10.1007/s00262-011-1010-x. Epub 2011 Apr 2.

PMID:
21461842
9.

Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice.

Stabile LP, Rothstein ME, Keohavong P, Lenzner D, Land SR, Gaither-Davis AL, Kim KJ, Kaminski N, Siegfried JM.

Cancers (Basel). 2010 Dec 1;2(4):2153-70. doi: 10.3390/cancers2042153.

10.

Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy.

Feinstein TM, Lai SY, Lenzner D, Gooding W, Ferris RL, Grandis JR, Myers EN, Johnson JT, Heron DE, Argiris A.

Head Neck. 2011 Mar;33(3):318-23. doi: 10.1002/hed.21444. Epub 2011 Jan 31.

11.

Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome.

Stabile LP, Dacic S, Land SR, Lenzner DE, Dhir R, Acquafondata M, Landreneau RJ, Grandis JR, Siegfried JM.

Clin Cancer Res. 2011 Jan 1;17(1):154-64. doi: 10.1158/1078-0432.CCR-10-0992. Epub 2010 Nov 9.

12.

Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer.

Srinivasan M, Parwani AV, Hershberger PA, Lenzner DE, Weissfeld JL.

J Steroid Biochem Mol Biol. 2011 Jan;123(1-2):30-6. doi: 10.1016/j.jsbmb.2010.10.002. Epub 2010 Oct 16.

13.

Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma.

Bao P, Potter D, Eisenberg DP, Lenzner D, Zeh HJ, Lee Iii KK, Hughes SJ, Sanders MK, Young JL, Moser AJ.

HPB (Oxford). 2009 Nov;11(7):606-11. doi: 10.1111/j.1477-2574.2009.00110.x.

14.

Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.

Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Lenzner DE, Jackson EK, Gorelik E, Lang S, Johnson JT, Whiteside TL.

Clin Cancer Res. 2009 Oct 15;15(20):6348-57. doi: 10.1158/1078-0432.CCR-09-1143. Epub 2009 Oct 13.

15.

A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer.

Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, Colonello K, Crowley-Nowick PA, Kelley JL, Price FV, Edwards RP.

Cancer Immunol Immunother. 2010 Feb;59(2):293-301. doi: 10.1007/s00262-009-0750-3.

PMID:
19690855
16.

PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.

Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM.

J Immunol. 2009 May 1;182(9):5240-9. doi: 10.4049/jimmunol.0803245.

17.

Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer.

Brell JM, Matin K, Evans T, Volkin RL, Kiefer GJ, Schlesselman JJ, Dranko S, Rath L, Schmotzer A, Lenzner D, Ramanathan RK.

Oncology. 2009;76(4):270-4. doi: 10.1159/000206141. Epub 2009 Mar 4.

PMID:
19258727
18.

Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells.

Zhang G, Liu X, Farkas AM, Parwani AV, Lathrop KL, Lenzner D, Land SR, Srinivas H.

Mol Endocrinol. 2009 Feb;23(2):146-56. doi: 10.1210/me.2008-0431. Epub 2008 Dec 23. Erratum in: Mol Endocrinol. 2010 Feb;24(2):471.

Supplemental Content

Loading ...
Support Center